Aicuris to be acquired by Asahi Kasei for $920 million

26 February 2026

Germany’s Aicuris revealed it has entered into a definitive agreement under which Asahi Kasei (TYO: 3407), through its wholly owned US subsidiary Veloxis Pharmaceuticals, acquire all shares of Aicuris for a total of 780 million euros (~$920 million).

The acquisition will enable Asahi Kasei to strategically expand its portfolio of therapies designed to treat severe viral infections, addressing critical infectious complications faced by patients undergoing hematopoietic stem cell transplant, solid organ transplants and other immunologically driven conditions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical